ADHD Key Stats
- Alcobra Ltd. (ADHD) Jumps: Stock Up 6.4% - Tale of the Tape Zacks Dec 11
- Nasdaq stocks posting largest volume increases Dec 6
- Stifel Nicolaus Starts Alcobra Ltd. (ADHD) at Buy Street Insider Dec 4
- Alcobra to Present at the 25th Annual Piper Jaffray Healthcare Conference noodls Dec 2
- Alcobra Ltd. Announces New Findings on Diminished Abuse Potential of Its Proprietary Drug Candidate, MG01CI noodls Nov 22
- Alcobra's CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 9
- U.S./Canada daily earnings hits & misses Nov 7 - 1820 ET Reuters Nov 7
- Alcobra Ltd. Reports Third Quarter 2013 Results noodls Nov 7
- Alcobra (ADHD) Widens Q3 Loss to $0.28/Share Street Insider Nov 7
- Alcobra Successfully Completes Enrollment in Comparative Phase II Study of Attention and Cognitive Function Benefits in Patients With PI-ADHD noodls Nov 5
ADHD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alcobra is up N/A over the last year vs S&P 500 Total Return up 28.99%, AEterna Zentaris down 49.77%, and Idera Pharmaceuticals up 301.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for ADHD
Pro Strategies Featuring ADHD
Did Alcobra make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Alcobra Ltd is a biopharmaceutical company which engaged in the development and commercialization of its proprietary drug, MG01CI, to treat attention deficit hyperactivity disorder.